Obstacle Avoidance amongst Parkinson Disease Patients Is Challenged in a Threatening Context

Table 1

Clinical information of the Parkinson disease patient group.

Patient	Age (yr)	Disease duration	Sex	UPDRS-III*		Symptoms (OFF)			Medication
				ON	OFF	Bradykinesia	Action Tremor	Resting Tremor
1	80	15	M	28	45	Y	Y	Y	Levodopa; Levodopa (sustained release)
2	69	4	M	18	40	Y	Y	Y	Levodopa
3	76	8	M	6	24	Y	Y	N	Levodopa; Levodopa (sustained release); Pramipexole
4	75	1	M	6	17	Y	N	Y	Levodopa
5	81	7	M	16	33	Y	Y	Y	Levodopa; Pramipexole
6	54	10	F	5	14	Y	N	Y	Levodopa; Pergolide mesylate; Amantadine
7	54	22	F	21	43	Y	Y	Y	Levodopa; Pramipexole
8	80	2	F	38	54	Y	Y	Y	Levodopa; Amantadine
9	63	2	F	22	58	Y	Y	Y	Levodopa
10	65	11	F	21	34	Y	Y	N	Levodopa; Pramipexole
Mean; (SD)	69.7; (10.3)	8.2; (6.6)		18.1; (10.5)	36.2; (14.7)

∗The Unified Parkinson Disease Rating Scale-III (motor component—questions 18–31), with higher scores indicative of greater motor deficit.